ストックスクリーナーアプリを入手
23.42
3.50%
-0.85
アフターアワーズ：
23.42
前日終値:
$24.27
開ける：
$24.21
24時間の取引高:
1.51M
Relative Volume:
0.84
時価総額：
$3.87B
収益：
-
当期純損益:
$-451.71M
株価収益率:
-7.2595
EPS:
-3.2261
ネットキャッシュフロー:
$-462.19M
1週間 パフォーマンス:
+1.52%
1か月 パフォーマンス:
+32.54%
6か月 パフォーマンス:
+31.80%
1年 パフォーマンス:
+166.14%
1日の値動き範囲:
$22.57
$24.28
1週間の範囲:
$22.40
$24.60
52週間の値動き範囲:
$8.245
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
23.42 | 4.01B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-10-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-25 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 開始されました | Bernstein | Mkt Perform |
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $30 to $47 - Moomoo
Dyne Therapeutics(DYN.US) Director Sells US$17.86 Million in Common Stock - Moomoo
Form 4 Dyne Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Dyne therapeutics director Jason Rhodes sells $17.86 million in stock - Investing.com
Dyne Therapeutics (DYN) director-linked Atlas funds sell 777K shares under 10b5-1 plan - Stock Titan
Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien - Barchart.com
Form 144 Dyne Therapeutics For: 7 July By Investing.com - Investing.com India
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
(DYN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Dyne Therapeutics (DYN) Surges Over 5% as Momentum Builds Above Key SupportRSI Oversold Picks - dars.gov.et
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? - The Motley Fool
DYN Stock Price | Analyst Target 42.43 & Strong Buy Consensus - eToro
Price to book forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
DYNE THERAPEUTICS INC (DYN) Stock Chart - ChartMill
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? - The Motley Fool
Dyne therapeutics director Jason Rhodes sells $10.7m in stock - Investing.com UK
Dyne therapeutics director Jason Rhodes sells $10.7m in stock By Investing.com - Investing.com South Africa
Form 4 Dyne Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$10.71 Million in Common Stock - Moomoo
Atlas funds linked to Dyne (DYN) director sell 504,695 shares - Stock Titan
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma - Barchart.com
Form 144 Dyne Therapeutics For: 29 June By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics - The National Law Review
Form 144 Dyne Therapeutics For: 26 June By Investing.com - Investing.com Nigeria
Price to sales forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
DYN Initiated Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
Enterprise value to EBIT forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Dyne therapeutics director Jason P Rhodes sells $5.65m in stock - Investing.com UK
Price to earnings forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Price to earnings forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com - Investing.com Australia
Enterprise value to revenue forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes - Stock Titan
Dyne Therapeutics(DYN.US) Director Sells US$5.65 Million in Common Stock - Moomoo
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing - marketscreener.com
TD Cowen Initiates Dyne Therapeutics at Buy - Moomoo
TD Cowen Initiates Dyne Therapeutics(DYN.US) With Buy Rating - Moomoo
Dyne Therapeutics stock initiated at buy by TD Cowen on platform - Investing.com UK
Dyne Therapeutics stock initiated at buy by TD Cowen on platform By Investing.com - Investing.com Australia
Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares - Stock Titan
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):